CRELD2: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: CRELD2

NCBI ID: G79174

CRELD2

CRELD2: A Promising Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The lack of effective treatments for this condition has led to a high prevalence of morbidity and mortality.CRELD2, a protein with cysteine-rich and EGF-like domains, has been identified as a promising drug target and biomarker for chronic pain. This article will provide an overview of CRELD2, its functions, and potential as a drug target and biomarker for chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can have significant impacts on an individual's quality of life and overall health. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with costs associated with chronic pain reaching $60 billion annually.

The treatment of chronic pain is a complex and multifaceted process that requires a combination of approaches, including pharmacotherapy, lifestyle modifications, and physical therapy. While there are numerous medications available for the treatment of chronic pain, the lack of effective new treatments remains a major challenge in managing this condition.

CRELD2: A Potential Drug Target and Biomarker

CRELD2, which stands for cysteine-rich with EGF-like domain protein 2, is a protein that has been identified as a potential drug target and biomarker for chronic pain.CRELD2 is a 12-kDa protein that contains four domains center: a catalytic domain, a transmembrane region, an intracellular domain, and a C-terminal region.

The catalytic center of CRELD2 is an active site for protein-protein interactions and is involved in the regulation of cellular processes, including cell signaling, protein folding, and metabolism. The transmembrane region of CRELD2 is responsible for maintaining the protein's structural integrity and for regulating its expression. The intracellular domain of CRELD2 is involved in the protein's localization and interaction with other cellular components, while the C-terminal region contains a potentially conserved functionally unique domain that may be involved in protein-protein interactions.

CRELD2 has been shown to play a role in the regulation of pain perception and the modulation of pain fibers. In animal models of pain, CRELD2 has been shown to contribute to the development and maintenance of pain. For example, CRELD2-/- mice showed reduced pain-like behavior compared to wild-type mice, suggesting that inhibition of CRELD2 may be a potential therapeutic approach for the treatment of chronic pain.

In addition to its potential role in pain perception, CRELD2 has also been shown to be involved in the regulation of pain modalities, including pain processing and neuroinflammation. For example, CRELD2 has been shown to contribute to the recruitment of immune cells to the site of pain, which may contribute to the exacerbation of pain.

Potential Therapeutic Strategies for CRELD2-Induced Chronic Pain

Given the potential involvement of CRELD2 in the regulation of pain perception and modalities, there is significant potential for the development of drugs that target CRELD2 as a potential therapeutic approach for the treatment of chronic pain.

One approach to targeting CRELD2 is to use small molecules that can modulate its activity. Drugs that inhibit the activity of CRELD2 or enhance its stability have been shown to be effective in reducing pain in animal models of pain. For example, inhibitors of the protein kinase CKL has been shown to be effective in reducing pain in rat models of pain.

Another approach to targeting CRELD2 is to use antibodies that can specifically recognize and target the protein. This approach has been shown to be effective in reducing pain in animal models of pain. For example, antibodies against CRELD2 have been shown to be effective in reducing pain in rat models of pain.

Importance of

Protein Name: Cysteine Rich With EGF Like Domains 2

Functions: Protein disulfide isomerase (By similarity). Might play a role in the unfolded protein response (By similarity). May regulate transport of alpha4-beta2 neuronal acetylcholine receptor (PubMed:16238698)

The "CRELD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRELD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets